Redeye maintains the valuation of Abliva at SEK 1.4 per share, an upside of 49% from current levels. An important milestone has been achieved today with the start of phase Ia/b with KL1333 in patients. We maintain a positive outlook on the company and on the prospects of its most advanced asset.